Manjeet K. Rao

The University of Texas Health Science Center at San Antonio — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index3.9kcitations196works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(41), Cancer-related molecular mechanisms research(27), Estrogen and related hormone effects(16), Cancer-related gene regulation(16), MicroRNA in disease regulation(15)

Publications196 total

Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Anti-tumor Immunity
Cancer Research·2025
Supplementary Data from Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma
2025Open Access
Epigenetic silencing of DNA sensing pathway by FOXM1 blocks stress ligand-dependent antitumor immunity and immune memory in triple negative breast cancer 2641
The Journal of Immunology·2025Open Access
CSIG-19. UNRAVELING THE MECHANISMS OF THOC7 IN MEDULLOBLASTOMA PROGRESSION
Neuro-Oncology·2025Open Access
Figure S2 from Targeting DDR2 for Treating Pancreatic Cancer
2025Open Access
Figure S1 from Targeting DDR2 for Treating Pancreatic Cancer
2025Open Access
Figure S3 from Targeting DDR2 for Treating Pancreatic Cancer
2025Open Access
Data from Targeting DDR2 for Treating Pancreatic Cancer
2025Open Access
Figure S4 from Targeting DDR2 for Treating Pancreatic Cancer
2025Open Access
Supplementary Tables 1-4 from Targeting DDR2 for Treating Pancreatic Cancer
2025Open Access
Abstract B030: Targeting DDR2 for Treating Pancreatic Cancer
Cancer Research·2025
Supplementary Figure S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S2 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S3 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary table S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S2 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
page 1 of 10Next →

Frequent Co-authors

Yidong Chen(20), Ratna K. Vadlamudi(14), Yufei Huang(11), Panneerdoss Subbarayalu(11), Suryavathi Viswanadhapalli(11), Miles Wilkinson(10), Jia Meng(8), Santosh Timilsina(8), Rajeshwar R. Tekmal(8), Gangadhara R. Sareddy(8), Uday P. Pratap(7), Subapriya Rajamanickam(6), Nourhan Abdelfattah(6), James A. MacLean(6), Benjamin Onyeagucha(5), Sanjay Bansal(5), Kristin A. Altwegg(5), Xiao‐Nan Li(5), Andrew Brenner(5), Lin Zhang(4)